Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.
暂无分享,去创建一个
B. Monk | I. Vergote | S. Pignata | D. Cibula | H. Denys | Shweta Jain | J. Baurain | A. Westermann | I. Boere | E. Van Nieuwenhuysen | D. Lorusso | K. Tewari | D. Collins | R. O’Cearbhaill | C. Gennigens | D. Iglesias | S. Banerjee | I. Soumaoro | C. Andreassen | Kristine Madsen